Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038543 · ClinicalTrials.gov registry record · Phase 1
Hydroxyproline Influence on Oxalate Metabolism
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02038543: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02038543 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02038543, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Primary hyperoxaluria is an inborn error of metabolism that results in marked overproduction of oxalate by the liver. The excess oxalate causes kidney failure and can cause severe systemic disease due to oxalate deposition in multiple body tissues. Metabolic pathways that lead to oxalate are poorly understood, but recent evidence suggests that hydroxyproline may play a role. Sources of hydroxyproline include the diet and bone turnover. If hydroxyproline can be confirmed as a significant factor in primary hyperoxaluria, diet modification might be of value in reducing the severity of disease. This protocol, in which hydroxyproline labelled with a cold isotope is infused intravenously in patients with primary hyperoxaluria, will allow the researchers to measure the amount of oxalate produced from hydroxyproline. The contribution of hydroxyproline metabolism to the amount of oxalate excreted in urine in will be able to be determined for patients with each of the known types of primary hyperoxaluria.
Interventions
- DRUG Hydroxyproline and Leucine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038543
The ClinicalTrials.gov registry entry for NCT02038543 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxyproline and Leucine is the first listed.
NCT02038543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02038543 about?
NCT02038543 is a clinical study titled "Hydroxyproline Influence on Oxalate Metabolism". Primary hyperoxaluria is an inborn error of metabolism that results in marked overproduction of oxalate by the liver. The excess oxalate causes kidney failure and can cause severe systemic disease due to oxalate deposition in multiple body tissues. Metabolic pathways that lead to oxalate are poorly...
What is the current status of trial NCT02038543?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2013-09. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02038543?
The interventions under investigation include: Hydroxyproline and Leucine (DRUG).
Who is sponsoring clinical trial NCT02038543?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.